Myria Biosciences

Myria Biosciences is at the forefront of developing a new class of therapeutic molecules that merge the key features of small molecules and biologics. Utilizing advanced techniques such as synthetic biology, directed evolution, and cell-based screening, Myria Biosciences engineers medical drugs aimed at difficult, previously undruggable targets. This innovative approach translates into potential cures for unmet medical needs, heralding a new golden age of natural products. The company operates in the biotech and pharmaceutical sectors, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. Myria Biosciences' business model revolves around the research, development, and commercialization of these novel therapeutic molecules, generating revenue through partnerships, licensing agreements, and direct sales of their proprietary drugs. The startup is a spin-off from ETH Zurich and collaborates with institutions like Frankfurt University and the Max Planck Institute to leverage cutting-edge technology and scientific expertise.

Keywords: synthetic biology, directed evolution, therapeutic molecules, undruggable targets, GEMMS, biotech, pharma, ETH Zurich, natural products, unmet medical needs.